It's a shame that Kimmel didn't provide a number to call for the tens of millions of Americans who have seen their premiums and out-of-pocket costs skyrocket under Obamacare's strictures.
In recent months, late-night talk show host Jimmy Kimmel has taken to scaremongering his audience with well-worn Democratic Party talking points regarding health care insurance policy. Between yuks, he occasionally accuses Republicans of being would-be baby killers, which is treated as an important political development because, well, Jimmy Kimmel is famous.
This week, the comedian was back to explain why the new Graham-Cassidy Republican "repeal" bill is bad news. There were only two things wrong with his monologue: Almost everything he said was either completely untrue or highly misleading, and his simplistic emotional appeal was completely disconnected from the real world.
The comedian's interest in policy was sparked by the harrowing experience of having a newborn son who suffered from a rare health condition. Thankfully, his boy is OK. "If your baby is going to die and it doesn't have to, it shouldn't matter how much money you make," said an emotional Kimmel in May. "I think that's something that, whether you're a Republican or a Democrat or something else, we all agree on that, right?"
Yes, everyone agrees. As far as I know, there isn't a single politician in America who has ever supported allowing babies to die because they are born with birth defects, even if the parents can't pay. Not pre-Obamacare, and not post-Obamacare.
In any event, after Kimmel's May rant, Louisiana Sen. Bill Cassidy showed up on his show to explain his position. These types of culture encounters shouldn't be dismissed, because the fact is most viewers are unaware of specific policies and have a notional understanding that's prejudiced by the establishment media's coverage. Cassidy came up with something he called the "Jimmy Kimmel Test," a test that no "family should be denied medical care, emergency or otherwise, because they can't afford it."
Kimmel claims that the new bill doesn't meet this threshold. "This guy, Bill Cassidy, just lied right to my face," the talk-show host said on Tuesday night during an extended political rant. He went on to say, "And by the way, before you post a nasty Facebook message saying I'm politicizing my son's health problems, I want you to know: I am politicizing my son's health problems." OK.
He explained: "Coverage for all? No. Fact, it will kick about 30 million Americans off insurance."
Not a single person would be "kicked off" his or her insurance. Rather, the Congressional Budget Office review of the AHCA found that of the 24 million Americans who would no longer have health insurance after an Obamacare repeal, 14 million would choose not to buy insurance in 2018 in the absence of a penalty. And if Obamacare were not repealed, the CBO projects another 6 million people would voluntarily leave the Obamacare markets. Now, if you don't believe Americans should be afforded the choice to leave or not buy insurance, just say that. No one is being kicked off.
Moreover, if Kimmel supports the individual mandate, Graham-Cassidy allows California to institute it—as I am sure it would.
Kimmel says: "Pre-existing conditions? Nope. If the bill passes, individual states can let insurance companies charge more if you have a pre-existing condition."
States would be allowed to apply for waivers to change what qualifies as an essential health benefit as long as they still preserve "adequate and affordable health insurance coverage" for people with pre-existing conditions. You may prefer price fixing to allowing states flexibility to try and fix these problems, but Graham-Cassidy does not break the "Jimmy Kimmel Test." Kimmel might not be aware that there is no plan in place that has government cutting checks after every surgery.
Kimmel then implored his audience to call Cassidy to stop the imaginary bill he had just described. It's a shame that Kimmel didn't provide a number to call for the tens of millions of Americans who have seen their premiums and out-of-pocket costs skyrocket under Obamacare's strictures. Is there no number available for those who are sick of being in exchanges that coerce them to buy plans they don't need that are sold by companies they don't like in fabricated, noncompetitive "markets" with dwindling choices?
Anyway, so went a monologue that could have been written by any liberal activist. Which is to say it was all about cheap zero-sum emotionalism. Kimmel doesn't believe Americans deserve the chance to reduce the cost of health care with market-based reforms on the state level, or in giving states any flexibility in catering their plans to their own citizens. Kimmel believes California and New York should spend more per capita and smaller states should suffer. Kimmel doesn't believe that individuals and families should be allowed to contribute to health savings accounts or use them to help pay ever-growing insurance premiums. Kimmel wants average Americans to suffer.
You see? Anyone can play this game.


text:
<?php
namespace Consolari\Entries;

interface EntryInterface
{
    public function format();
}

redpajama_set_name: RedPajamaGithub


text:
Cheerful locals engage in traditional games at the Temple of Heaven.
Beijing, the capital of China was once the seat of the Ming and Qing dynasty emperors. The word Beijing literally translates to 'Northern Capital'. Today the city is the political capital of the vast country with wide boulevards and modern buildings alongside ancient palaces and squares. Rich imperial history and China's rapid progress come together in an exciting mix in Beijing.
Words: Kalpana Sunder
Brightly coloured kites fashioned like mythical monsters dance above the treetops, and children frolic in the grass. The Long Corridor, the covered walkway, is an entertainment corridor with cheerful locals playing mahjong (tile-based game) or having a picnic. A troupe of local Uyghur dancers in traditional costumes, perform opera arias.
We are at Beijing's Temple of Heaven, the stage for the Emperor to appeal to the Heavens to give a bountiful harvest. Its most remarkable feature is the round, blue-roofed Hall of Prayer for Good harvests, constructed without nails.
The Emperor visited the temple thrice a year to request favour for a good harvest, pray for rain, and to show gratitude. The Emperor would fast in the Forbidden City before he performed the sacrifices in the Temple of Heaven.
It is surrounded by a lush park studded with ancient trees; we enjoy the nine dragon cypress, more than 500 years old, so called because it looks like nine dragons winding with each other.
For a glimpse of Old Beijing, we take a trip to the hutongs. The word 'hutong' is derived from the Mongolian word 'hottog' meaning water well. The first hutongs were built more than 700 years ago when the Mongols dug out wells and decided to live around them.
On a short tour of the modern architectural icons of Beijing, we visit the Bird's Nest or the National Stadium and the Water Cube - the ocean blue Olympic Aquatic centre made of Teflon which looks like plastic bubbles. Most impressive is the peculiar steel and glass doughnut-like CCTV building, which seems to represent modern Beijing.
The focal point of Wangfujing Street is the food market - steam-billowing vats and skewers of spicy meat from sizzling grills.
For more than 500 years, the Forbidden City was only accessible to Emperors of the Ming and Qing dynasties and their families. We are at the Southern Entrance (called the Meridian Gate), to the sprawling Forbidden City, the world's largest palace complex. We enter a large square with the Hall of Supreme Harmony, which used to be the scene of important ceremonies, where the Emperor ascended the throne, got married and celebrated the New Year.
We spend an afternoon at the multi-floored Silk Market filled with a mind-boggling variety of goods on sale. Bargaining is a must. Our last day is spent at a timeless Chinese tea ceremony. Beijing has a unique identity, a mix of the modern and the futuristic lying close together with the ancient and historical.
The Temple of Heaven was visited by the Emperors of the Ming and Qing dynasties for annual ceremonies.
For a glimpse of Old Beijing, visit the hutongs.
The ultra modern Water Cube or the Beijing National Aquatics Center.
Wangfujing Street is a world of neon lights and street food.
The Forbidden City was only accessible to members of the Ming and Qing dynasties.

redpajama_set_name: RedPajamaCommonCrawl


text:
Student Politics
Steel City Scene
Home » Posts by Trisha Gregorio
Wake up to the Cartoon Revolution
Trisha Gregorio • Mar 24, 2016 — (last modified) Mar 23, 2016 • Arts, Pop Culture
by Cartoons have been on the rise lately. Adventure Time, Steven Universe, Gravity Falls and Over the Garden Wall have gained substantial followings in the past year, and this audience doesn't look like it will be going anywhere any time soon. Sailor Moon got a reboot in commemoration of its 20th anniversary, and Digimon got a direct sequel. Tumblr has also witnessed the return of older cartoons, and bloggers are revisiting shows like...
[REVIEW] Firewatch will set your world alight
Trisha Gregorio • Mar 17, 2016 • Arts, Pop Culture, Reviews
by Firewatch is hands-down one of the most beautiful games I've ever encountered. I'd checked it out with zero idea what it would be about and what to expect, but the graphics of the start menu alone was all the convincing I needed to continue on. Firewatch is categorized under "first person adventure," and it follows a fire lookout named Henry on his first few days on the job. The story is jump-started by the disappearance of two...
[REVIEW] The Little Prince Mark Osborne's 2015 adaptation of The Little Prince reinterprets a poignant tale
Trisha Gregorio • Mar 10, 2016 • Arts, Film, Reviews
by Every year, I naively await the Oscars' Best Animated Feature Film. Every year, Disney proves itself to be the most powerful force in the animated world, and every year, I nod and grudgingly agree as yet another Studio Ghibli film gets sidelined. With Pixar's Inside Out setting the bar for animated films this year, Mark Osborne's The Little Prince was released at the Cannes Film Festival with relatively minimal fanfare. However,...
[REVIEW] Macbeth Justin Kurzel's Macbeth might boast an A-list cast, but its silence is its loudest achievement
Trisha Gregorio • Mar 3, 2016 — (last modified) Mar 5, 2016 • Arts, Film, Reviews
by When the list of nominees for the 2015 Cannes Film Festival came out, I was as excited for Justin Kurzel's Macbeth as I was for Mark Osborne's Le Petit Prince. Having closely watched both Roman Polanski's 1971 Macbeth and the modernized 2010 British television adaptation, you'd think I'd be tired of the play by now, but Shakespeare's Scottish tragedy once again proves itself a whirlwind of a masterpiece regardless of how it's...
The new Spring Awakening is ? Michael Arden's new interpretation of the popular musical sees the director prominently feature deaf actors and American Sign Language, in a move that only enhances the spectacle
Trisha Gregorio • Feb 25, 2016 — (last modified) Feb 27, 2016 • Arts, FEATURES
by With a Grammy category dedicated solely to musical theatre, it's safe to say that Broadway is largely defined by how good the music is. So when I heard that Broadway actor-turned-stage-director Michael Arden is taking Spring Awakening, a musical near and dear to my heart, and reinventing it with American Sign Language, my first thought was: how? Spring Awakening is, in the barest of definitions, a coming-of-age story. It's a rock...
Tweets by theSilhouette
INTERVIEW: #HamOnt\\\\\\\\\\\\\\\'s first CoCo Bubble Tea Store
SILVISION
Sex and the Steel City 2016
\\\\\\\\\\\\\\\'ROUND CAMPUS // Fall 2015: A Look Back — Economic Initiatives
\\\\\\\\\\\\\\\'ROUND CAMPUS // Fall 2015: A Look Back - Awareness
Hamilton is now home to a new location of the CoCo Bubble Tea franchise. With over 2,000+ storefronts worldwide, CoCo hopes to expand their audience to students and families in the Steel City. Video shot and edited by Phil Kim.
What would you like to see included in The Silhouette? Let us know by filling out our reader feedback survey: https://www.surveymonkey.com/r/CL2Y5QG
Along with our regular print issue, we will be releasing this year\'s Sex and the Steel City magazine on Feb. 11! Pick it up on stands, or read it online at thesil.ca.
We\'re continuing our series featuring McMaster University\'s initiatives — take a look at some of the fundraisers that occurred on campus this past fall
We have some great student initiatives at McMaster University; this series features some of the ones we were able to catch up with throughout the fall term of 2015
McMaster University's Student Newspaper Since 1930
Copyright © 2019 The Silhouette.


text:
NPA to appeal spy tapes judgment
By Corruption Watch 23 May 2016, 11:35
National director of public prosecutions Shaun Abrahams on Monday announced that the National Prosecuting Authority (NPA) will appeal the ruling of the North Gauteng High Court judgment on the so-called spy tapes and possible re-instatement of corruption charges against Jacob Zuma. The judgment – handed down on 29 April – set aside the 2009 decision to drop 18 charges of fraud and corruption, relating to 783 dodgy payments, against Zuma. Arguments were heard at the beginning of March. "My decision is strictly based on the judgment of the Pretoria High Court and not any other decision," Abrahams responded when asked if he had sought the opinion of Mokotedi Mpshe, the acting national prosecutions director at the time that the charges were dropped, in coming to this decision. "I will always do what is correct, irrespective of whether the individual is an ordinary person, a cabinet minister or a sitting president." He stressed that his team would not discuss the merits of the case with the media and would thus not prefer to be asked questions on that. "I believe it needs the decision of an appeal court," said Abrahams of the case. The DA had brought the case against three respondents, namely Mpshe; Leonard McCarthy, head of the Directorate of Special Operations (Scorpions), which was disbanded in 2009; and Zuma, who was not president at the time the charges were withdrawn. Mpshe's decision to withdraw the charges was based on an alleged political plot against Zuma by McCarthy and others, but his unilateral decision to do so was deemed irrational by the Pretoria High Court. The NPA first brought corruption charges against Zuma in 2007, but these were dismissed in September 2008 in the Pietermaritzburg High Court. The judgment was appealed and overturned in January 2009. The NPA was thus about to go ahead with its case against Zuma. However, on 31 March 2009 Mpshe listened for the first time to the spy tapes, and was so disturbed by what he said he heard – evidence of the McCarthy plot – that he withdrew the charges against Zuma. Mpshe's action triggered the DA's case, launched a week later. The 2016 judgment, setting aside Mpshe's decision, was handed down in the collective name of the court, and was not attached to any of the three judges.
Tags: National Prosecuting Authority, NPA, Corruption Watch, corruption, Jacob Zuma, Mokotedi Mpshe, spy tapes, Shaun Abrahams, Supreme COurt of Appeal
Investigator's testimony fingers Zuma, Shaik
Urban land in Zim: power, politics and corruption
What can you do to fight corruption?
Arms deal and Seriti Commission FAQ
Letter to the AU on African Anti-Corruption Day
Do Chinese aid projects in Africa worsen corruption? And if so, why?
Media invite: launch of CW's TRAC report Motsoeneng's options are running out


Azure is getting pretty good early reviews. The only problem is that the tools and platform require the application to be hosted in a service provider's datacenter, not your own. Meanwhile, competitors like VMware, HP and others are more than happy to let you build private clouds.
Early next year, Microsoft will begin beta testing Azure services that can blend private and service providers' clouds, letting your internal app -- say, a database -- access and update the larger cloud database. Unfortunately, the ability to build a purely private Azure may take a bit longer.
Meanwhile Redmond just bought Opalis, whose automation software can help control clouds.


text:
Spanish Resorts
The web's No1 Spanish travel resource.
Map of Spain
Spanish Cities
The Costa's
Menorca, Holiday Island Wrapped In History
January 22, 2008 Spanish Resorts 0 Comments
The island of Menorca, also known as Minorca, has long been a favorite among holiday travellers, so much so that the island is nicknamed, 'The Holiday Island'. Anyone familiar with the novels of author Patrick O'Brian, who wrote "Master and Commander", a recent movie starring global heartthrob Russell Crowe, knows that Menorca is a prime location setting for his high seas adventure novels.
These days however, Menorca is known for her sun-speckled beaches, incredibly blue waters, native attractions and exotic foods. The small island, which spans a mere 35 miles long and wide, is located in the Mediterranean Sea. Under Spanish control, the island has long been known, and visited, by travelers from around the world who wish to see two thousand year old, giant megalithic stone monuments as well as to absorb its rich pirate history. Pirates no longer use Menorca as a haven from Romans seeking them, but Menorca is just as popular as it always has been due to its beautiful landscapes, sheer cliffs, mysterious caves, sea life and laid-back vacation atmosphere.
However, the island, despite its gentle appearance, has a history rich in battles and military history. The British have long found Menorca to be one of the most popular holiday spots, though few know of its illustrious, if occasionly dubious, military history. Following recent incidents involving the British Royal Navy, the British people, proud of their military history and participation in the defense of freedom, may not be surprised to discover that another incident which involved the Royal Navy persists to this day, the roots of the incident rooted deep in the sands and ruins of British occupation on Menorca.
In 1757, a British sea admiral by the name of John Byng was shot by a firing squad because, according to his British peers, he failed to "do his utmost" to defend St. Phillip Fort against attack by French forces. It did not seem to matter to his peers, snug in their homes in England, that he was undermanned and commanded ships already damaged during previous skirmishes, nor that he probably saved the lives of his crewmen by sparing them battle which would most probably have hastened them to their doom. Byng was court-martialled, labelled a coward and executed on March 14, 1757.
Despite the passage of 250 years, Admiral Byng's descendants have attempted to gain him a posthumous pardon, who seems to have been in the wrong place at the wrong time, a time when sound judgment passed for cowardice during the traumatic Seven Years Wars fought between 1756 and 1763. Byng is buried in Bedfordshire. His epitaph reads, "To the perpetual disgrace of public justice, the honourable John Byng, admiral of the blue, fell a martyr to political persecution on 14th March in the year 1757, when bravery and loyalty were insufficient securities for the life and honour of a naval officer."
Menorca, a favorite holiday destination, is filled with historical memories and lessons to be learned if we but care to remember and listen to the voices and legacies of those who stepped on her hot, white sands before us. Visiting Menorca provides not only prime holiday favorites; sunshine, glistening ocean waves and warm, luxurious sands, but an opportunity to explore history, up close and personal.
Article source: www.articlesbase.com
Information about Menorca Real Estate can be found via propertymenorca.info For a guide to Malta, including details of Malta expedia holidays visit YourMalta.com , and for the Monaco GP visit YourMonaco.com
← Discover Menorca's Hidden Beaches
Getting The Most from your Trip To Menorca →
Discover Menorca's Hidden Beaches
January 22, 2008 Spanish Resorts 0
Getting The Most from your Trip To Menorca
Holiday Lets in Spain
Copyright © 2020 Spanish Resorts. All rights reserved.


Wanted to ask if anyone had applied for residency at the national police station here in Sanlucar?
You apply for the resident certificate not a card for EU residents, at the NATIONAL 'foreigners' police station in Jerez, Sanlucar do not deal with this. They will tell you what your wife will require if not currently an EU national.
You will need various photocopies and official documentation which only they can tell you want you need, as they can and will change their requirements at any moment.
Search for Jerez on the above website.
For padron this is completed at the town hall offices in Barrio Alto costs a few Euros. You will require a copy of your accommodation contract, plus probably copy of passports amongst one or two other possibilities...!!
Be prepared to go forwards and backwards...!!!
Thanks so much for this information, Ian.
Heading to the town hall tomorrow. Wish me luck.
Luck, patience and a whole lot more I guess..!


text:
Fredrik Kekalainen
Founder & CEO Send a Message Connect @fkekalainen
Fredrik Kekalainen: fearless leader, technologist, innovator, and entrepreneur. In 2010, he founded Enevo to create a more efficient, technology-driven waste management and recycling company for an increasingly urbanized world.
Fredrik started his first software technology company in 1996 while still in business school. The company was sold successfully in 1999.
He continued his startup journey as co-founder of Fathammer Inc., a venture capital-backed developer of graphics software systems for embedded and mobile device manufacturers. Fathammer was acquired by Japan-based Acrodea, Inc., shortly before its IPO in October of 2006.
Since then, Fredrik has taken his tech expertise to the waste world, finally updating an industry that hasn't changed in decades. Enevo currently has more than a dozen patents to its name and is used in 6 continents of the world.
When he's not changing the waste world, Fredrik enjoys sailing the Boston Harbor and being outdoors with his family.


After a long and anticipated break from blogging, i have decided to come back and really work on my blog full time and really focus on it. I have always struggled with writing and i believe thats the one thing which makes it harder for me and not believing in myself. So today, I'm back with a new post all about my current favourite perfume.
After smelling Viktor Rolf Bonbon perfume on a sample that you get in Vogue about year ago, i have always remembered the scent. In April, my Mum and I went to Turkey and she very nearly bought it, but in the end she didn't pick it up. I was secretly happy as then it meant that i could pick it up for myself and so i did. I ordered it pretty much the week we returned and have used it everyday since. Its just about to run out, which is pretty much good timing as i go on holiday Friday so i am planning to pick up a new one at the Airport, but it will most probably be a Jo Malone one.... oopsie.
The scent of Bonbon is very sweet. It isn't something which i tend to go for, but i just love the scent that lingers and it really does stay on you for a whole day. Its not too sickly sweet, but its enough to make you want more. I love applying this in the mornings and at first i thought it could be too overpowering for the daytime, but as you get used to use it, i think it suits the daytime very much, but it is also great for the evening.
Overall, its a lovely perfume with a gorgeous bottle and a somewhat overbearing price like every perfume. I am the worst person for describing scents, so i can really only recommend going to give it a spray if your in a boots/superdrug/ perfume shop. I think mine is the 50ml and it was £60 which is expensive, but its one of my top 3 perfumes which i can't wait to pick up again.
I hope you enjoyed this post and you can expect to see a lot more content from me on my blog and also on instagram and twitter. I hope you have a great weekend and thank you for reading!


text:
HomeLatest News & PoliticsYakubu Gowon slumps at Ejoor's burial ceremony
Yakubu Gowon slumps at Ejoor's burial ceremony
May 3, 2019 Yomie Latest News & Politics, Today's Trending.... 2
Yakubu Gowon, former military head of State has slumped during the funeral of David Akpodiete Ejoor in Ovwor-Olomu Community, Ughelli south local government, Delta state.
The incident happened at the grave side while the funeral oration was on going on Friday.
The former military head of state was promptly rushed by some top echelons of the military into the special tent for emergency resuscitation while Ifeanyi Okowa, governor of Delta state and James Ibori, former governor of the state, dashed into the tent to ensure he recovers.
NAN reports that military as well as the Delta state ambulances were immediately moved in to front of the tent in case the former head of state's health deteriorates further.
After a while, Ibori and Okowa were seen exiting the special tenth, an indication that the former army general has recovered.
The 84-year-old general was military head of state between 1966 and 1975.
Igbo most misrepresented ethnic group in Nigeria – Governor Okorocha
Nigeria in worst period of insecurity- Yakubu Dogara
FG No Longer Cares About Rivers State, Wike Laments
March 1, 2017 AdeLove Latest News & Politics, Today's Trending.... 1
Governor Nyesom Wike of Rivers state has lamented that the Federal Government no longer cares about projects execution in the state because the state does not matter in its development programme. Wike said that his […]
Senate leader Ahmad Lawan tasks FG on North East Commission chairmanship pick
October 26, 2017 AdeLove Latest News & Politics, Today's Trending.... 0
Senate leader, Ahmad Lawan, on Thursday, urged the Federal Government to appoint credible and competent persons to manage the affairs of the newly established North East Development Commission (NEDC). Lawan (APC Yobe North) said that […]
Kemi Adeosun, has reassured Nigerians, economic programmes will return the country to growth.
November 29, 2016 AdeLove Latest News & Politics, Today's Trending.... 1
The Minister of Finance, Kemi Adeosun, has reassured Nigerians that a cocktail of economic programmes being pursued by the current administration will definitely return the country to growth. Speaking on the topic 'Changing the Growth […]
Suny says:
Oh too bad
Gowon is a very nice man
However at his age, he just needs to slow down and cut down drastically his public activities
He doesn't need to attend every public function and engagement
One cannot cheat nature
There is time for everything
Flying all over Nigeria to attend public events is not ideal, healthwise, for an 84 year old
@Suny, I agree completely with you on the need for the old man to slow down and choose meticulously the public functions he should attend,going forward.


text:
Henson scores 19 points, game-winning FTs for Wagner
CBK Headlines
Michigan adds Smith to Howard's staff
Kentucky AD named NCAA men's hoops chair
Cleveland St. fires Felton after 2 years
UNC returning for 1 game at Carmichael
NCAA charges NC State with 4 violations
Iowa lands Valpo transfer Evelyn
Ex-Vols F Burns transferring to Winthrop
Florida F Stokes to transfer
UConn put on probation for 2 years
Marquette's Nelson takes over Holy Cross
BALTIMORE (AP) Corey Henson scored 19 points, including the game-winning free throws with 22 seconds left, and Wagner beat Morgan State 68-66 on Saturday.
After Henson's free throws, Morgan State missed a 3-pointer and a follow in the final six seconds.
Wagner led 37-35 at halftime and the lead went back and forth in the second half. Michael Carey, who had 10 points, put Wagner ahead 64-63 with a bucket and AJ Sumbry, with 11 points and 10 rebounds, extended the lead to 66-63 with 1:10 remaining. Isiah Graves' 3-pointer tied it but his foul put Henson on the free-throw line.
Henson made 5 of 8 3-point tries. Shack Scott added 10 points and JoJo Cooper 11 rebounds for the Seahawks (3-5), who snapped a three-game losing streak.
Graves, a JC transfer, scored a career-high 20 points and Phillip Carr had 17 points and 12 rebounds for the Bears (3-7). Kyle Thomas added 12 points.


Imagine rushing out of a cramped boat into a thigh deep water while machine gun fire and artillery shells are falling all around you. All you see ahead are flat sand beaches with no cover and imposing concrete fortifications set on cliffs which are manned by hostile troops who want to kill you and your fellow soldiers. Events similar to these were experienced by the brave Allied soldiers who partook in The Battle of Normandy, also known as D-Day. It marked the turning point of World War II in Europe and although there were other pivotal battles in Europe, Middle East and North Africa like Stalingrad, Tobruk, and the Battle of the Bulge, none matched its importance. No single battle was more significant to the Allied victory over Germany and the future of post war Western Europe than D-Day. It provided the Allies with a long awaited second front to combat the Nazis in Europe and put numerous battle operations in motion that ultimately led to the Allied troops' victory in World War II. D-Day also helped to dramatically shorten the war, as after 5 years of Nazi dominance and occupation of most of Europe, the Germans surrendered 11 months after the Normandy invasion.


Today's card is a shaker birthday card using stamp / die sets from The Stamps of Life. I used some older papers / buttons from Fancy Pants Designs, called It's Your Day. I stamped the cone design on the paper & cut it with the matching die. The ice cream shaker was die cut with the coordinating die & the shaker portion was simply cut with a circle die. The circles in the background paper were outlined with a glimmer pen. The cone was mounted with craft foam, and the card was finished with a spatter of buttons and gems. The sentiment was cut with and IO die set. Thanks for looking.
hello Patti! super sweet, the ice cream cone shaker is a brilliant idea...luv! so glad you played along with us at simon says stamp wednesday challenge!


text:
'Project Eternity' director talks stealth, stats and crafting
Since the Project Eternity Kickstarter campaign ended last October, Obsidian Entertainment has been flooding backers' inboxes with information. In another attempt to give fans an inside look at the game, project director Josh Sawyer sat down with RPG Codex to answer a few questions.
Stealth in Project Eternity will be a little more complex than your average RPG. Characters will have "a radius around them (based on their individual Stealth skills) that represents the range at which a creature's perception radius can notice them."
Casting a spell, or any deliberate action will drastically increase this radius, but that doesn't mean enemies will be alerted. Merely "bumping" an enemy's radius will cause them to investigate, giving players a chance to flee. Of course, this will turn into an all out attack if a character doesn't react quickly enough.
Stats will function differently than the usual Dungeons and Dragons affair as well. For simplicity's sake, one statistic will affect things like weapon damage or accuracy, as opposed to different weapons requiring different stats. While this might diminish the satisfaction of crafting the perfect character, it does make each individual that much more versatile.
Also on the topic of stats, crafting will be less fruitful than one might think. Every recipe found will only be used to "create consumables or to add/upgrade properties on existing items." Special weapons and armor will not be available to craft, however they will be available through drops, quest lines, etc.
Project Eternity can still be backed on the official site, and is scheduled to release in Q2 2014.
Via: Polygon


text:
EU H2020
ACTIVATE YOUR
OWN DEFENSE
MaxiVAX is pleased to announce that Dr Bruno Osterwalder, MD, former Chief Medical Officer, will become a Senior Advisor and member of MaxiVAX's Scientific Advisory Board, as part of the planned leadership transition.
Dr Osterwalder was MaxiVAX's Chief Medical Officer from October 2020 until October 2022, whereby he was responsible for leading MaxiVAX's clinical, regulatory, and medical programmes.
Dr Osterwalder is highly regarded for his international clinical research and development, having held various roles in the pharmaceutical industry. He is a board-certified haematologist and oncologist, with more than 15 years' experience of academic clinical practise in internal medicine, haematology, and oncology. This was followed by 19 years at F. Hoffman-Roche Basel, where he was part of the global drug development and strategic portfolio management in haematology, (immuno-) oncology and renal and cancer anaemia. He then spent 6 years at Merck Serono in Darmstadt, where he was actively involved in the global haemato-oncology and immune-oncology development. Since 2015, Dr Osterwalder is acting as a consultant, CMO or board director to smaller pharmaceutical companies in Europe, the USA and China.
MaxiVAX is delighted that Dr Osterwalder will continue to support the company as a member of the Scientific Advisory Board toward our goal of reshaping cancer treatment through active, personalized cancer immunotherapies.
MaxiVAX is pleased to announce the scientific article "Immortalized human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology" has been published in the Journal of Molecular Therapy – Methods and Clinical Development 26, 441-458.
The article describes the generation of a stable human myoblast cell line that was genetically modified to secrete diverse therapeutic proteins, including the cytokine adjuvant human granulocyte-macrophage colony-stimulating factors (GM-CSF), a viral protein (SARS_CoV-2 spike protein) and antibodies (anti-CD20 and anti-CTLA4).
The scientific output and writing were the result of a collaborative endeavour between MaxiVAX and University of Geneva Hospital.
IHM – Mol Ther MCD 2022
MaxiVAX is pleased to announce that Dr Thomas Mehrling has been appointed Chief Medical Officer as of 1st October 2022.
Dr Mehrling will lead MaxiVAX's clinical development strategies and plans, as well as the implementation of clinical, analytical and operational activities. He will also contribute to the further advancement of MaxiVAX's Encapsulated Cell Technology platform, that can be customized to produce a variety of therapeutic proteins.
Dr Mehrling brings over 25 years of experience in the Pharma industry to MaxiVAX. He has held various leadership positions in drug development in oncology and haematology, medical affairs, clinical operations, and business development.
Prior to joining MaxiVAX, Dr Mehrling served in a number of key roles including as the Senior Global Medical Director at F. Hoffmann-La Roche Basel. He was also before this CEO at Mundipharma EDO GmbH and International Director in Oncology Strategy at Mundipharma International Ltd.
Dr Mehrling received his M.D. from the University Hospital in Frankfurt and his PhD from University of Frankfurt in Germany.
Dr Mehrling's full biography can be viewed here: MaxiVAX Team
Last week, Julien Grogg, COO and Head of Tech Dev of MaxiVAX presented recent progress on the development of our Encapsulated-Cell Platform Technology at the Swiss Cancer Center Leman's annual retreat. The event took place at the International Conference Center of Geneva. The development of MaxiVAX' platform technology is the result of a fruitful collaboration with UNIGE and HUG.
Prof. Nicolas Mach, Chief Scientific Officer and Co-founder of MaxiVAX, presented MaxiVAX's latest results in immunotherapy development at the Festival of Biologics, Basel on 3 November, 2022.
Read more: Festival of biologics
MaxiVAX is attending the Bio-Europe 2022 in Leipzig, Germany, 24 – 26 October.
Bio-Europe 2022 is the largest Biopharma networking event in Europe, attracting a wide range of business leaders, such as: senior executives of leading biotech companies, business development teams from large and midsize pharmaceutical companies, investors, and other industry experts.
Read more: https://informaconnect.com/bioeurope/
MaxiVAX is participating and presenting a scientific poster at the Cancer Immunotherapy Conference CICON 2022 in New York, 28 September – 1 October.
The congress focuses on the « Translating Science into Survival, » and features talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.
Read more: http://www.cancerimmunotherapyconference.org/
Poster CICON 2022
MaxiVAX and the University of Geneva Hospital (HUG) team were awarded the Best Poster Award – Investigational Immunotherapy at ESMO 2022 in Paris.
The poster highlights the safety, feasibility and efficacy of MVX-ONCO-1 in 34 patients with solid tumors.
Best poster and ESMO poster
MaxiVAX is participating and presenting a scientific poster at the ESMO Congress 2022 in Paris 9 – 13 September.
The ESMO Congress will bring together key opinion leaders, clinicians and scientists to brainstorm, debate and explore topics in the field of medical oncology.
Read more: https://www.esmo.org/meetings/esmo-congress-2022
Poster ESMO 2022
Interview with Mrs Ksenija Pavletic, MaxiVAX's Chairwoman and Prof Nicolas Mach MaxiVAX's Co-founder and Chief Scientific Officer in the Entreprise Romande, a publication by the "Fédération des Entreprises Romandes Genève" (in French).
MaxiVAX has completed a Phase I clinical trial, whereby a total of 34 patients were treated. The results of this clinical trial demonstrated that MaxiVAX's personalised immunotherapeutic treatment is feasible, safe and well tolerated.
MaxiVAX's on-going Phase II Head and Neck clinical trial shows promising results. The interim data review shows 75% of patients reaching the 6 months survival endpoint, which is above the initial target of 50% of patients reaching 6 months survival. With these promising results, MaxiVAX plans to complete this study by the end of 2023.
While remaining optimistic, Mrs Ksenija Pavletic shares her insights on the financing challenges that many start-ups such as MaxiVAX often face. She also adds that it would require approximately four more years to bring MaxiVAX's immunotherapeutic product to the market.
Entreprise Romande : Interview MaxiVAX
MaxiVAX will be participating and presenting a scientific poster at the Immune Responses in Cancer Infection (IRCI) meeting, Lyon on 15- 17th June. The IRCI2022 is organized by researchers from two leading centres in Lyon, the CIRI and CRCL.
The IRCI meeting will bring together international prominent scientists and clinicians to discuss their recent immunological findings in fundamental and clinical research.
Read more: Immune Responses in Cancer Infection meeting
Poster MaxiVAX IRCI meeting
MaxiVAX will participate in the European Oncology Partnering Convention, a two-day event entirely dedicated to open innovation in Oncology – Bordeaux, France on 12 -13 May, 2022.
Read more: European Oncology Partnering Convention
Interview with Prof Nicolas Mach, Co-founder and Chief Scientific Officer in Switzerland's "Bilan" Magazine (in French). Prof Mach explains about MVX-ONCO-1 and the Phase II clinical trial conducted in 4 sites in Switzerland, aimed at tackling Head and Neck Squamous Carcinoma (HSNCC). All patients enrolled in the study have confirmed diagnosis of HNSCC, state III/IV and have previously failed several courses of standard therapy. Preliminary results of this clinical trial are very encouraging and MaxiVAX intends to complete this study in the following 6 to 9 months.
MaxiVAX aims to raise capital to further advance clinical studies of the company's lead therapeutic products in other solid cancers. A partnership with Minaris Regenerative Medicine, a Contract Development and Manufacturing and Organisation, has been concluded, to scale-up the manufacturing of MaxiVAX's lead product MVX-ONCO-2.
Bilan : MaxiVAX veut traiter tous les cancers
Prof. Nicolas Mach, co-founder and CSO of MaxiVAX, presented the bench to bedside development of MVX-ONCO at HUG's Café de l'Innovation.
Read more (French) : HUG café de l'innovation
Geneva – March 3rd, 2022 – MaxiVAX will attend the RNA Leaders World Congress live in Basel, March 16-17, 2022. The event is a gathering of leading pharmas and biotechs as well as academic institutions that develop RNA medicines. MaxiVAX will participate on the partnering platform.
MaxiVAX announces the completion of enrolment into the MVX-ONCO-1 phase I – part 3 – clinical trial in Advanced Solid Tumors with encouraging safety and efficacy signals.
Geneva – January 27, 2022 – MaxiVAX announced today the completion of enrolment into the phase I trial of MVX-ONCO-1 in advanced solid tumors. The study's part 3 was an extension to recruit in total 35 patients following positive safety profile and encouraging efficacy signals from part 1&2. The initial phases of the study were completed in 2016 and 2018 respectively, and were designed to enroll patients with rare types of advanced solid tumors in order to collect additional safety, efficacy and translational research data.
MaxiVAX is now very proud to announce that the last patient started its treatment in October 2021 and will end the short-term follow-up in March 2022. The company plans to publish the results of this study shortly thereafter.
MaxiVAX to take over the sponsorship of SAKK 11/16 phase II clinical study in HNSCC.
Geneva – October 19, 2021 – MaxiVAX announced today that the company has taken over the sponsorship of SAKK 11/16 phase II clinical study in patients with Head & Neck Squamous Cell Carcinoma. The long lasting and appreciated relationship with SAKK will continue, as SAKK will remain involved in the context of a Sponsor-CRO collaboration.
As the new sponsor of SAKK 11/16, MaxiVAX held an Investigator meeting on the 6th of October 2021. The highly awaited event saw the active participation of 4 investigators and clinical study staff from our 4 recruiting sites (Lausanne, Zurich, St. Gallen and Geneva).
The investigator meeting presented an excellent opportunity for the participants to have discussions on the latest protocol amendment and challenges faced by each site. It drew valuable feedback from the floor and the inputs from the investigators shed new insights on the scientific and operational aspects of the trial. The session resulted in an alignment and commitment from the CRO, the Sponsor and the investigators. MaxiVAX would like to thank the participants, and especially the investigators and the clinical study staff for their involvement.
MaxiVAX to advance its second-generation personalized immunotherapy – MVX-ONCO-2 – to studies in solid tumors.
Geneva – October 6, 2021 – MaxiVAX announced today that the company has filed a Clinical Trial Application for a multicenter phase I study of MVX-ONCO-2 in patients with advanced solid tumors. This advancement is the result of several years of development and close collaboration with experts in immuno-oncology and cell encapsulation technologies.
MVX-ONCO-2 follows the scientific principles of MVX-ONCO-1, MaxiVAX' first asset in clinical development. The phase I study evaluating the safety, tolerability, and efficacy of MVX-ONCO-1 in patients with advanced solid tumors will be completed in Q1-2022. The encouraging safety and efficacy signals observed in this open label study led to the development and initiation of the phase II PoC study in Head & Neck Squamous Cell Carcinoma (SAKK 11/16), which is currently enrolling patients.
By developing MVX-ONCO-2, a second asset to enter clinic in Q2 2022, MaxiVAX has created a new cell encapsulation technology with platform capabilities and optimized features for long term GMCSF delivery in vivo. The company believes that this technology will further improve the efficacy profile of MVX-ONCO-1 without compromising its very good safety profile. A total of 6 patients with advanced melanoma (3) and advanced solid tumors (3) will be enrolled in this phase Ia study of MVX-ONCO-2.
MaxiVAX is also investigating expanding the use of its encapsulation technology to potentially bring therapeutic solutions to the extensive unmet medical need in other chronic disease such as inherited bleeding disorders or lysosomal storage diseases.
CELL ENCAPSULATION COULD ENHANCE ANTIVIRAL VACCINES
Immunotherapy techniques developed in oncology to combat cancerous cells have great potential for fighting viruses. A research team from the University Hospitals of Geneva (HUG) and the University of Geneva (UNIGE), in Switzerland, in collaboration with MaxiVAX, a spinoff of both institutions, developed an innovative technology called « cell encapsulation ». Originally designed to stimulate immunity to fight cancer, the COVID-19 pandemic motivated the scientists to broaden the scope of their technology to test its effectiveness against viruses. The first results of a pre-clinical study are very encouraging and can be discovered in the journal Vaccines.
Latest news headline
MVX-ONCO Explained
MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership
GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 — MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH ("Minaris"), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such as chordoma, head and neck, and other solid tumors.
Geneva study against SARS-COV-2 gets underway
Geneva University Hospitals (HUG), the University of Geneva (UNIGE), the Infectious Disease Research Centre at Laval University in Quebec (Canada) and MaxiVAX – a Geneva-based company specialising in biotechnology – are working together to develop a SARS-CoV-2 vaccine. This joint research programme aims to create a vaccine combining an immunostimulator and a specific coronavirus target, namely the spike surface protein. This is administered by intradermal injection with the immunostimulator, whose role is to produce an adjuvant capable of stimulating the immune system. It is implanted under the skin via cell encapsulation, a technology that is already undergoing Phase II clinical tests led by HUG in collaboration with MaxiVAX in the area of cancer immunotherapy.
The first pre-clinical tests for perfecting the vaccine will be carried out on mice in the coming weeks. If preliminary tests prove encouraging, a clinical trial could be set up in the near future.
MaxiVAX awarded €2,785,000 European Commission grant and announces successful closing of its Series B 2 round for an amount of CHF 5 million
MaxiVAX wins grant among 94 projects funded out of 2,015 applications
Closing of Series B 2 round of CHF 5 million from new and existing investors
Funds used for Phase 2 cancer programs
MaxiVAXSA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, announced today that it had been awarded a European Commission grant of €2,785,000, thanks to the Horizon 2020EIC Accelerator Programme.MaxiVAX was among 94 funded projects out of 2,015 applicants, thereby ranking among the top 4% of high-tech companies.
The company also reported the successful closing of a Series B 2 roundof CHF 5 million from new and existing investors, whose continuing support the company is particularly grateful.
© Copyright 2020 - MaxiVAX
Dr Thomas Mehrling
Dr Thomas Mehrling, MD, PhD, joined MaxiVAX's executive team as a Chief Medical Officer in October 2022.
Dr Mehrling has over 25 years of experience in the Pharma industry, having held various leadership positions in business development, medical affairs, clinical operation, and development of novel therapeutics in oncology and haematology.
Prior to MaxiVAX, Dr Mehrling served as the Senior Global Medical Director at F. Hoffmann-La Roche Basel, where he worked with international cross functional teams on the strategic development of key assets in haematology.
Before F. Hoffmann-La Roche, he served as the CEO at Mundipharma EDO GmbH, and as the International Director in Oncology Strategy at Mundipharma International Ltd. As the CEO, he oversaw overall operations and delivered strategic plans for a start-up company. Under his leadership, the company rapidly progressed with four early-stage oncology assets, two small molecules and two antibody conjugates; driving them from preclinical development to clinical trial. As the International Director in Oncology Strategy, he has experience working with worldwide associated companies to maximize revenues of the established oncology products, establish relationship with market stake holders and regulators to facilitate commercialisation, laying the foundation for Mundipharma EDO GmbH.
Dr Mehrling received his M.D. from the University Hospital in Frankfurt, Germany and his PhD from University of Frankfurt.
Dr Mehrling is a member of American Society of Clinical Oncology (ASCO), American Association for Cancer Research, American Society Hematology (ASH), European Society for Medical Oncology (ESMO), European Hematology Association (EHA).
Macarena Diaz
Macarena Díaz joined MaxiVAX in June 2022 as CMC & Quality Manager.
Macarena has accumulated over 8 years of experience, primarily in the field of Quality Assurance and also in Regulatory Affairs and Pharmacovigilance.
Macarena worked for different multinational companies. She started her career with Saval laboratories in the regulatory affairs department before moving to Sanofi to work in Quality Assurance. More recently, she worked for Ferring as Quality Assurance country responsible and carried out other consultancy activities for pharmaceutical distributors. She was in charge of implementing and maintaining quality systems, performing quality audits and managing relationship and documentation with third parties.
Macarena received a pharmacist degree from University of Chile.
Olivier von Rohr
GMP Manufacturing Technician
Olivier von Rohr joined Nicolas Mach's research group in 2017 and is in charge of the GMP manufacturing of MVX-ONCO-1. During his studies as Biology Laboratory Technician (2012-2015), he gained experience in genetic research, microbiology and toxicology.
Marie-Claude Belkouch
Quality Assurance Manager – Manufacturing
Marie-Claude Belkouch joined Nicolas Mach's research group in 2009. She graduated from the Laboratory Technician School in tropical parasitology and in health and community care. After more than 25 years in molecular biology and immunology laboratories at the faculty of medicine in Geneva, Marie-Claude started working in oncology. She gained 10 years of experience in the manufacturing of cell-based immunotherapies and has developed an expertise in quality assurance.
Valentin Saingier
Valentin Saingier joined Nicolas Mach's research group in 2020 and is in charge of the GMP manufacturing of MVX-ONCO-1. He holds a Bachelor degree in biotechnologies. He worked in different resaearch areas such as Alzheimer, stem cells cryopreservation, genetic analyses and vegetal pathology, both in wet lab and GMP manufacturing facilities.
Emily Charrier, Ph.D.
Emily Charrier, joined MaxiVAX in February 2018, as Research Associate. At MaxiVAX, she is in charge of research projects in cancer immunotherapy and immune reactions induced by immunotherapy. Prior to MaxiVAX, Emily worked 10 years in the development of immune-monitoring for anti-cancer immunotherapies. She was awarded a Master's degree from Grenoble University in France and a PhD in immunology from the University of Montreal in Canada.
Muriel Urwyler
Scientific Associate
Muriel Urwyler joined Nicolas Mach's research group in 2016 to work on the development of MaxiVAX's next generation cell line. More recently, she also joined the manufacturing team. She holds a Bachelor and a Master of Science in biochemistry from the University of Geneva. Prior to joining Nicolas Mach's research group, Muriel worked as a Research Laboratory Technician in oncology, in the development of a vaccine against cerebral tumors. She also worked in the development of novel cell therapies to treat diabetes.
Jessica Renaux, M.Sc.
Sr. Clinical Trial Manager
Jessica Renaux joined MaxiVAX in August 2020 as a Senior Clinical Trial Manager.
Prior to this, Jessica gathered 14 years of experience in drug discovery and development, both in the big pharma and not-for-profit organisation environments. After an early career as a medicinal chemist at GSK UK, she held different positions within the GSK early clinical development organisation, as a Clinical Data Manager, Clinical Study Manager and as a Clinical Lead for multiple small molecule and biopharmaceutical assets in the immuno-inflammation area. More recently, she led the set-up and conduct of a large pivotal multi-country phase III trial for a novel antibiotic within the GARDP Foundation based in Geneva Switzerland.
Jessica received a Chemistry "Diplôme d'Ingénieur" from Ecole Nationale Supérieure de Chimie de Montpellier (France) and a Master of Biomolecular Engineering from Montpellier University.
Julien Grogg, M.Sc., PMP
VP, Technology Development
Julien Grogg joined MaxiVAX in January 2014 to launch and lead the First In Human clinical trial of MVX-ONCO-1. He is now serving as Vice President of Technology and leads the development of MaxiVAX's novel product platform from early proof of mechanism to clinical translation. Julien has over 15 years of global pharma/biotech experience in both preclinical and clinical development of drugs, medical devices, cell therapy products and ATMPs under the auspices of the FDA, the EMA and Swissmedic. Amongst others, Julien filed and maintained market access and CE mark registration dossier of an implantable cell encapsulation product in Europe and in Mexico. He is the co-inventor of 2 patented medical products harnessing cell encapsulation technology.
Born in Switzerland, Julien is a Biomedical engineer by training and holds a M.Sc. in Clinical Research from the University of Edinburgh. He is also a certified PMP(r) from the Project Management Institute.
M.Sc., PMKsenija Pavletic Aranicki, M.Sc., MBA
Board Member, Deputy CEO
Mrs Pavletic Aranicki joined MaxiVAX Board of Directors in May 2020. She has over 20 years of global experience in the pharmaceutical industry in both large pharma companies as well as start-up biotech. Mrs Pavletic has a succesfull track record in building up commercial organizations, product launches, market access, business development activities (licensing deals), public and private fund raising and M&A deals. She is currently the CEO of a specialty pharma Company PregLem and is also serving as an entrepreneur in residence for Jeito Investment Fund.
Mrs Pavletic holds an MSc in Biotechnology from Zagreb University (Croatia) and an MBA from Webster University in Geneva (Switzerland).
Nicolas Mach, MD
Nicolas Mach is one of the co- fonder of MaxiVAX. His scientific expertise on cell-based cancer immunotherapy is the basis for the patented technology developed by MaxiVAX. Prof Mach is deputy Head of the Oncology Division at the Geneva University Hospital (HUG) and Head of the Clinical Research Unit and member of the Clinical Trial Unit bureau at HUG. The Clinical Research Unit headed by Nicolas Mach runs over 50 clinicals trials in oncology from Phase I to Phase III, mostly in the field of cancer immunotherapy. Nicolas Mach is the principal Investigator of more than 20 clinical trials. His research team is responsible for both the manufacturing of the clinical garde products from the SwissMedic certified Cell Therapy Facility of HUG and the development of novel cell lines and encapsulation devices for the stable and prolonged production of immunostimulatory proteins including monoclonal antibodies.
Salina Arope, PhD
Salina Arope joined MaxiVAX in 2017 as an Office Manager. Since January 2020, she is also the Project Coordinator forMaxiVAX's H2020 EU project.
Salina has previously worked at the Swiss Institute of Bioinformatics, University of Lausanne and EPFL, among other places. With a background in Molecular Biology, she provides general and scientific administrative support to members of the MaxiVAX team.
Salina received a Bachelor's degree from University of California (Davis), a Master of Biology from California State University of Long Beach, California and a doctorate degree in Biology from University of Lausanne.
Sirja Nelson
Sirja joined MaxiVAX in 2020. Prior to that she worked 20 years in the financial sector. In the last 15 years, she managed the administrative and financial tasks of an international family office. She now provides administrative and organizational support for the MaxiVAX office.
RÉMI VERNET, M.ENG
Rémi Vernet joined Nicolas Mach's research group in 2012 and works on the development of MaxiVAX's cell-based therapies in preclinical models, as well as in clinical setting. He is in charge of implementing the immune monitoring startegy of the company in collaboration with subject matter experts. Rémi is also in charge of supervising trainees in Nicolas Mach's research group.
Following his Engineering studies in biotechnologies and therapeutic strategies, he worked 4 years in Paris on cell therapy and protocol development. He worked in different public hospitals as well as a private laboratory in ISTEM (Thelethon's laboratory). He then decided to focus on a pharmaceutical drug screening project.
Adrien Engel
R&D Associate, Technology Development
Adrien Engel joined MaxiVAX in November 2020. He supports the executive team to develop MaxiVAX' next encapsulated cell technologies from the proof of mechanism to clinical phase.
Adrien worked on treatments based on dendritic cell vaccination and subcutaneous cellular implants against autoimmune diseases. He holds a Master's degree in synthetic biology from Paris Descartes University. He recently was awarded a PhD in immunology from the University of Lausanne.
Fabien Courtout
Fabien Courtout joined Nicolas Mach's research group in 2022 and is in charge of GMP manufacturing of MVX-ONCO-1. He holds a Master's degree in Biotechnologies. He has worked as laboratory technician in Yeast biology and genetic research. He also performed genetic test and FACS data analysis for pharmaceutical groups.
Bruno Osterwalder, M.D., FFPM
Dr Bruno Osterwalder joined MaxiVAXs executive team as a consultant in 2020. He is a board-certified hematologist and oncologist with 15 years of academic clinical practice in internal medicine, hematology and oncology (Swiss board certifications). This was followed by 19 years of experience in functions with increasing scientific and managerial responsibilities in global drug development and strategic portfolio management at F. Hoffmann-Roche Basel in the areas of hematology, (immuno-) oncology and renal and cancer anemia (global approvals for Xeloda in breast and colon cancer, Rituximab in DLBCL and Mircera in renal anemia), and over 6 years at Merck Serono Darmstadt (Tepotinib, approval in Japan in NSCLC), including experience in Japan and China and a focus on early POC stages, translational medicine and biomarker questions, and with broad experience in interactions with regulatory authorities worldwide. Since 5 years, his experience in in-licensing evaluations resulted in a worldwide consulting function primarily for biotech's. Dr. Osterwalder is a member of ASCO, AACR, ASH, ESMO and SITC.
Clarence Peter
Mr. Clarence Peter is one of the three founders of MaxiVAX and an active Board member since its incorporation in December 2005. He is a senior partner of the law firm Kellerhals Carrard Geneva; advisor of multiple national and international firms with a focus on new technologies and med-tech. He has a large experience in assisting commercial clients in all stages of their development including litigation, cross-border transactions and M&A. Mr Clarence Peter is proud to be an entrepreneur, dedicated to the value creation.


text:
Xylem Inc.
Xylem Named to Barron's 100 Most Sustainable Companies
Xylem Inc. (NYSE: XYL), a leading global water technology company, has been ranked number 10 on Barron's inaugural 100 Most Sustainable Companies list, which was announced in its February 3, 2018 issue. Xylem was also ranked number 2 on Barron's Special Report: The Most Sustainable I...
Xylem Provides Expanded Support for Relief Efforts in Puerto Rico
Xylem announced plans to expand its support for the ongoing recovery and rebuilding efforts in Puerto Rico in the aftermath of the devastating effects of Hurricane Maria. The Company has pledged financial support, including matching employee contributions, as well as a new effort to bring clean w...
Xylem Affirms Its Strong Support for the Paris Climate Agreement
Following yesterday's announcement that the United States will withdraw from the Paris Climate Agreement, Xylem, a leading glob...
Xylem Employees Volunteer More Than 21,000 Hours with Local Organizations in 2016
Employees from Xylem (NYSE:XYL), a leading global water technology company that is dedicated to solving the world's most challenging water issues, logged more than 21,000 volunteer hours in 2016 in activities aimed at providing and protecting safe water resources and educating people about water,...
Xylem Employees Celebrate Inaugural Global Month of Service by Logging More than 7,000 Volunteer Hours with Local Organizations
To commemorate its fifth anniversary, Xylem (NYSE:XYL), a leading global water technology company dedicated to solving the world's most challenging water issues, launched its inaugural Global Month of Service. The initiative aimed to advance Xylem's commitment to build a culture of volunteerism a...
Thai Students Take Top Honor at 20th Jubilee Celebration of Prestigious International Student Competition in Stockholm
Xylem Inc. (NYSE: XYL), a leading global water technology company dedicated to solving the world's most challenging water issues, congratulates Sureeporn Triphetprapa, Thidarat Phianchat and Kanjana Komkla of Thailand, the winners of the 2016 Stockholm Junior Water Prize (SJWP), the most prestigi...
Xylem Launches World's First Wastewater Pumping System with Integrated Intelligence
Xylem, (NYSE: XYL), a leading global water technology company dedicated to solving the world's most complex water issues, has developed another breakthrough technology, launching the world's first wastewater pumping system with integrated intelligence at the IFAT 2016 trade show (30 May-3 June). ...


text:
Indian Country Today video news report for March 13, 2019, with Vincent Schilling
byVincent Schilling
Missionary troubles on Pine Ridge, Adam Beach discusses his role in Juanita, Kinsale Hueston recognized by TIME and Deb Haaland makes HERstory once again...
Watch the video news report here
Greetings and She:kon everyone, this is Vincent Schilling and I am the associate editor of Indian Country Today and your host for this week's Video News Update. With this video update, Indian Country Today will bring you some of our top stories to hit the site.
Does Pine Ridge have the unfortunate distinction of being a poster child for Native American poverty?
Read the article: Seasonal complaint: 'Missionaries are on our reservation!'
According to a report by Mary Annette Pember, that statement is true. In the story, several residents have long handed out flyers warning tribal citizens about potential mistreatment and the rights of missionary organizations to private information. According to Pember, there are a series of reports of aggressive and demeaning treatment of Lakota spirituality, baptizing Lakota children without permission and using humiliating poverty porn to fundraise and promote a colonial agenda. There are also some allegations of sexual abuse and financial misdeeds due to these organizations' failure to conduct adequate background checks. Pine Ridge has one church for every 388 people, second only to Indianapolis with one church for every 289 people. Read the full story by Pember by following the story link below.
Adam Beach discusses his Netflix role in 'Juanita' and says his costar, Academy Award nominee Alfre Woodard 'is a priceless gem'
Read the article: Adam Beach discusses Netflix role in 'Juanita' says Alfre Woodard 'is a priceless gem'
On March 8, 2019, Netflix released 'Juanita' starring Acadamy-Award nominated actress Alfre Woodard and co-starring Adam Beach. The film was directed by Clark Johnson and was adapted from a screenplay by Roderick M. Spencer, which was based on the novel Dancing on the Edge of the Roof, by author Sheila Williams. The movie explores the life of a frustrated woman, Juanita, who is taken advantage of by her children and who often dives into a personal fantasy world involving the handsome Blair Underwood, who plays himself often sitting in his underwear, romanticizing Juanita. She eventually meets a chef, who is a veteran suffering from PTSD named Jess, played by Adam Beach. The story also explores the healing nature of a traditional powwow. Adam Beach says he learned a lot from Woodard, calling her a priceless gem. The movie Juanita is now on Netflix.
Read the article: Kinsale Hueston, Navajo, one of TIME Magazine's 'People Changing How We See the World'
The 19-year-old Navajo poet has already been rubbing elbows with the likes of Bethany Yellowtail and movie director Ava DuVernay before becoming featured as one of the TIME Magazines' 'People Changing How We See the World' In an interview with Kinsale, the article which posted on International women's day, describes how she got the well-deserved recognition and where her aspirations will take her into the future.
Read the article: Deb Haaland becomes the first Native American woman to sit in Speaker's chair and preside over the House Floor
On March 7, Representative Deb Haaland (D-NM-01) became the first Native American woman to sit in the Speaker's chair during a debate on H.R. 1, the For the People Act. The For the People Act is House Democrats' transformative bill aimed at ending corruption in politics and ensuring fair access to the ballot box. "When a young woman of color sees me in the Speaker's Chair, I want them to think 'I can do that,' that's part of why I'm here," said Representative Deb Haaland. "I want to help those who have not been represented before to identify with me and identify with Congress. It's their Congress too – it belongs to all of us." After Haaland took the rostrum, Congresswoman Sharice Davids, fellow Native American woman in Congress, posted the following powerful image on Twitter: Watching my friend Rep Deb Haaland become the first Native American woman to sit in the speaker's chair and preside over the house floor. #RepresentationMatters
THANKS FOR WATCHING Leave a comment below on our site. You can register with a few quick clicks. You can comment on stories, reply to other readers and add to the conversation.
Also check out my #NativeNerd column posted every Friday. Last Friday was my review of Captain Marvel.
Native Nerd Movie Review: Captain Marvel and the 'cat' that stole the movie
Again, Thanks for watching this week's ICT video news report. I am Vincent Schilling, associate editor of Indian Country Today. Follow me on Twitter at @VinceSchilling.
Have a great day! Ona and Nia:wen.
Follow Indian Country Today's associate editor Vincent Schilling (Akwesasne Mohawk) on Twitter - @VinceSchilling
Email - vschilling@indiancountrytoday.com
Celebrating (not) Mad Wayne Day
EditorMary Annette Pember
Residents demand accountability in fatal shooting of Chippewa man
EditorRichard Walker
US House: The president's racist comments provoke 'fear and hatred'
EditorCronkite News
New Trump administration rule makes asylum harder for Central Americans
Alaska arts agency: 'We're closing today'
Joaqlin Estus
Indigenous led San Diego Pride
David Cournoyer
'This is not the end' Alaska legislators fight budget cuts with 'urgency'
Go back where? Trump's racist tweets hits panel that included Deb Haaland
EditorMark Trahant
'Poetry is about listening' says Poet Laureate Joy Harjo


conditions of a bank loan may not be the best fit for your financial needs.
than a bank could lend it to you, your needs might be better met by a hard money lender.
12 months long, though in some cases they may extend to anywhere from two to five years.
lenders can be a lifeline.
What types of properties can I get a hard money loan for?
we can get you set up with the right, trustworthy source with little hassle on your part.
When would a hard money loan be better for me than a traditional loan?
have the same institutional restrictions as banks, they are usually easier to work with.
Sounds good! What do I need to secure a hard money loan?
on the borrower's record as long as the borrower can make the down payment.
their house, car, or other valuable commodity by putting it up as collateral for the loan.
the value of the property enough to pay back the loan with interest.


In which languages is SignRequest available?
What is the benefit of activating this integration?
SignRequest values the authenticity of your signed documents. In case there ever is a dispute about when exactly the document has been signed you need to be able to verify the date and time of signing. In case two signers have a different version of the signed contract you also need to be able to validate which one is the original one.
For this purpose SignRequest already seals the signed document with a digital certificate and adds a timestamp of our own server to the signing log. In for example Adobe Reader the digital certificate is visible by the green checkmark. If the document is changed the seal is broken and the green checkmark indicates the signature is no longer valid.
In adddition, SignRequest sends the hash codes of the documents by email. These hash codes are unique for each document and can be used to validate the authenticity of the signed document and the signing log.
As an extra option SignRequest can now add the hash code to the LTO Network Blockchain. This allows signers to validate if the hash code is valid and allows for an additional timestamp.
Where can I activate this within SignRequest?
You can activate this feature if you have a paid SignRequest account in the advanced options of your team settings.
SignRequest will also, for testing purposes and future developments implement this feature for (a part of) the free users and/or for paid users that did not activate this feature themselves. In that case however this will not be visible in the signing log. Although this is completely anonymous users can also actively opt out if they wish to do so.
SignRequest has been reviewing and testing Blockchain technology for several years. Although we believe it is unclear what the future will bring, we do feel it's a great technology and that electronically signing documents is a good use case for Blockchain projects. That's why we want to be at the forefront of this technology and explore it further.
We're not sure yet. We'll be testing how our market reacts to this new feature and explore our next steps together with our partners.
How to view your document proof in LTO Network?
After you have activated the use and visibility of LTO Network you can click on the link in the signing log to see if the transaction is valid.
How does the 'unlimited documents' policy works?
How to remove or delete a team account?
For questions have a look at our help center or contact us here.


Houston's Project Row Houses (PRH) is offering bus tours of public art created by the founding artists of PRH. The tour will also feature discussions with artists Jesse Lott, Floyd Newsum, Bert Samples, and George Smith.
This evening, March 14, and Wednesday, March 16 from 6:30-8pm, Project Row Houses (PRH) will host two Wikipedia edit-a-thons. The Black Lunch Table (BLT) project is an ongoing collaboration between artists Jina Valentine and Heather Hart which, in its 10-year existence, has sought to fill holes in the documentation of contemporary art history. BLT invites the the public to create, update, and improve Wikipedia articles pertaining to the lives and works of visual artists of the African Diaspora.
Along the same vein, PRH and BLT are also holding Black Lunch Table Recording Sessions on Tuesday, March 15, and Thursday, March 17 from 6:30pm-8:30pm. The BLT Recording Sessions take "the lunchroom phenomenon as its starting point" (refreshments provided) for dialogue and conversations. Session 1 is open to visual artists and art workers of African descent and will focus on the gathering of collective histories. Session 2 is open to the all and will focus on "the divisions and connections that exist within our community, while also laying out new productive relationships to continue the movement for dismantling institutional racism." RSVP for the BLT events here.


A crew from the PAC Dance Team pose in front of a sign at the filming of America's Got Talent.
Walden Grove High School's PAC Dance Team appears to perform a dance inspired by "Alice in Wonderland" in an episode of America's Got Talent that airs Tuesday, July 31.
When Sahuarita's Walden Grove High School PAC Dance Team performed on the popular show America's Got Talent earlier this month, they got a standing ovation before they even began dancing.
The Sahuarita teens will appear on the show's thirteenth season again 7 p.m. Tuesday, July 31 on NBC (Ch. 4) for a "Judge Cuts" episode. If they make it through, they'll perform in the live shows.
From photos provided to us by the show, it looks like Tuesday's performance is "Alice in Wonderland" inspired. Check out the video of the dance at a homecoming assembly here.
Mixing hip-hop hits with the "Wizard of Oz" won the team a spot in this latest round of the talent competition.
The Sahuarita students received tons of buzz over the routine when they performed it at a homecoming assembly and posted a video on YouTube nine months ago. It has since gotten 2.8 million views and caused that standing ovation. You can watch it here.
This isn't the first time they've gotten this kind of attention. You may remember the school's Pixar performance from last year (if not, you have to check it out). That video has 2.6 million views.
Led by coach and dance instructor Kristi Lopez, the team also received numerous awards in state competitions.
Lopez does all of the team's choreography, music selection, set design and costuming, using music and movies as inspiration.
Click here to read a story we wrote about the team last year when they won the state championships for hip-hop dance.
A version of this story appeared on This Is Tucson on July 9, 2018.
The Performing Arts Crew recently took first place in Arizona for the third time in a row.
A fight with her boyfriend left a Sahuarita woman injured and both arrested, police said Monday.


Small changes in the way you use energy around your home and business can add up, saving you energy every day.
These tips are a great start, but if you would like to do even more, check out our Rebates and Home Energy House Call information.
Install more energy efficient lighting by replacing your current lighting with LEDs.
Switch your incandescent exit signs to LED exit signs.
Replace appliances with ENERGY STAR® models.
Add automatic lighting controls, like occupancy sensors in restrooms.
Ensure your air vents are clear of obstruction.


Tom of Finland rug. Photography courtesy of Henzel Studio.
In a welcome confluence of progressive sensibilities, Austere, the innovative showcase of Scandinavian design in downtown Los Angeles, is hosting an exhibition of artist carpets and pillows crafted by the Swedish luxury rugmaker Henzel Studio. The show, Henzel Studio: Collaborations/Heritage, marks the U.S. debut of new carpet designs by Nan Goldin, Richard Phillips, and Helmut Lang, as well as the launch of a capsule collection dedicated to the artist Tom of Finland (Touko Laaksonen, 1920–1991).
Richard Phillips rug. Photography courtesy of Henzel Studio.
Helmut Lang rug. Photography courtesy of Henzel Studio.
Created in collaboration with Tom of Finland Foundation, the floor covering line comprises 12 hand-tufted carpets and one fantastic, freeform hand-knotted rug, all made in Nepal of silk and wool. (For those Tom aficionados who can't quite afford a high-end handmade carpet, the offering also includes three rather alluring cash-and-carry pillows.) The collection is ultimately a testament to both the revolutionary vision of Tom of Finland and the extraordinary craftsmanship of Henzel Studio, which has miraculously captured the artist's mastery of line, form, and shadow.